Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients - Slideshow (NASDAQ:TARA) 2025-12-04
Protara TherapeuticsProtara Therapeutics(US:TARA) Seeking Alpha·2025-12-04 06:03

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]